ABSTRACT
Objective To analyze the clinical efficacy and toxic reaction of Tegafur,Gimeraciland Oteracil Potassium Capsule combined with Gemcitabine chemotherapy for patients with radical resection for advanced gallbladder carcinoma.Methods The clinical dataof 135 patients with advanced gallbladder cancer who were admitted to the 1 st Affiliated Hospital of Zhengzhou University and supported after the gastrectomy by the pathology from June 2007 to June 2012 were retrospectively analyzed.All patients were divided into three groups by different therapeutic regimens,operation groups (Radical resection or Extended radical resection of gallbladder carcinoma) with 47 cases,chemotherapy A group (Tegafur,Gimeracil and Oteracil Potassium Capsule combined with Gemcitabine chemotherapy after Radical resection or Extended radical resection of gallbladder carcinoma) with 52 cases,and chemotherapy B group (5-Fluorouracil combined with Oxaliplatin chemotherapy after Radical resection or Extended radical resection of gallbladder carcinoma) with 36 cases.We collected the dates of all patients with the median survival time and the 1,3 and 5-year survival rate after operation,and counted the rate of major toxic reaction after chemotherapy.Results There were no significant differences in the general date of three groups (sex,age,tumor size,CA19-9,CA125,TNM stages,with or without cholecystolithiasis,operation methods,operation complication),The chemotherapy A group and chemotherapy B group had no differenceswiththe median survival time and 1,3 and 5-year survival rate after operation.There were significant differences in the median survival time and 3,5-year survival rate after operation between the operation group and chemotherapy A group (or between the operation group and chemotherapy B group).There were significant differences in the rate of whole toxic reaction and the rate of toxic reaction beyond Ⅲ degree between chemotherapy A group and chemotherapy B group.Conclusions The treatment of Tegafur,Gimeracil and Oteracil Potassium Capsule combined with Gemcitabine chemotherapy for patients with radical resection of advanced gallbladder carcinoma has a lower rate of whole toxic reaction and rate of toxic reaction beyond Ⅲ degree than 5-Fluorouracil combined with Oxaliplatin chemotherapy,and for patients with advanced gallbladder carcinoma,the frontal treatment can obviously prolong the median survival time and effectively improve the 3 and 5-year survival rate after operation.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of capecitabine and tegafur gimeracil and oteracil potassium synchronous radiotherapy in the treatment of recurrence after radical resection of colon cancer. METHODS:A total of 150 patients with recurrent after radical resection of colon cancer in our hospital during Jan. 2012-Dec. 2012 were divided into group A and B ac-cording to random number table,with 75 cases in each group. Both groups received three-dimensional conformal radiotherapy. Group A was additionally given capecitabine 2.5 g. Group B was additionally given tegafur gimeracil and oteracil potassium,40 mg,bid for body surface area <1.25 m2,50 mg,bid for body surface area ranged 1.25-1.50 m2 and60mg,bid for body surface ar-ea<1.50 m2. Clinical efficacies of 2 groups were compared;1-year,2-year,3-year survival andⅢ-Ⅳdegree toxic effect were fol-lowed up. RESULTS:The total response rate of group B was 86.67％,which was significantly higher than 66.67％ of group A, with statistical significance(P<0.05). 1-year,2-year,3-year survival rates of group B were 93.335,72.00％,58.67％,which was significantly higher than 74.67％,53.33％,41.33％,with statistical significance(P<0.05). The median disease progression time of group A was 8.0 months,which was significantly shorter than 9.5 months of group B,with statistical significance (P<0.05). There was no statistical significance in Ⅲ-Ⅳ degree toxic effect between 2 groups (P<0.05). CONCLUSIONS:Compared with capecitabine,tegafur gimeracil and oteracil potassium combined with three-dimensional conformal radiotherapy show significant therapeutic efficacy for recurrence after radical resection of colon cancer,can control disease progression,prolong the survival time and don't increase the risk of toxic effects.
ABSTRACT
OBJECTIVE:To compare therapeutic efficacy and safety of lobaplatin or cisplatin combined with tegafur,gimeracil and oteracil potassium in the treatment of advanced metastatic breast cancer.METHODS:A total of 160 patients with advanced metastatic breast cancer were randomly divided into observation group and control group,with 80 cases in each group.Control group was given Cisplatin injection 30 mg/m2 intravenously,every 3 weeks Tegafur,Gimeracil and Oteracil Potassium capsules 50 mg orally after meal,twice a day,for consecutive 14 days.Observation group was given Lobaplatin for injection 30 mg/m2 intravenously,every 3 weeks+Tegafur,Gimeracil and Oteracil Potassium capsules (same usage and dosage as control group),every 3 weeks.A treatment course lasted for 3 weeks,and both groups received 2 courses.Short-term efficacies (ORR、DCR),chemotherapy effects of lymph node,lung,bone and liver,ADR and long-term efficacy were compared between 2 groups.RESULTS:After treatment,ORR(67.50％ vs.46.25％),DCR(85.00％ vs.66.25％),ORR of lymph node metastasis (71.43％ vs.47.83％),ORR of lung metastasis (60.71％ vs.40.00％),DCR of lung metastasis (78.57％ vs.56.00％),ORR of bone metastasis (28.57％ vs.16.67％),1-year survival rates (75.00％ vs.52.50％) and 2-years survival rates (42.50％ vs.17.50％) of observation group were significantly higher than control group;the incidence of chemotherapy ADR in observation group was significantly lower than control group (43.75％ vs.70.00％),with statistical significance (P＜0.05).There was no statistical significance in lymph node metastasis DCR,bone tissue metastasis DCR,liver metastasis ORR and DCR,or half year sarvival rate between 2 groups (P＞0.05).CONCLUSIONS:Compared to cisplatin combined with tegafur,gimeracil and oteracil potassium,lobaplatin combined with tegafur,gimeracil and oteracil potassium show better short-term therapeutic efficacy,therapeutic efficacy of lymph node metastasis,bone metastasis and lung metastasis,more than 1-year long-term therapeutic efficacy and safety in the treatment of advanced metastatic breast cancer.
ABSTRACT
Objective To evaluate the efficacy and adverse reaction of continuous low-dose oral Tegafur,Gimeracil and Oter-acil Potassium Capsules in combination with small dose of transcatheter arterial chemoembolization(TACE)in the treatment of pri-mary hepatocarcinoma patients.Methods A total of 92 primary hepatocarcinoma patients who were unable or unwilling to surgery. Patients were divided into treatment group and control group,with each consisted of 46 cases.The treatment group was given con-tinuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules in combination with small dose of TACE,and the control group was given small dose TACE.All study subjects were reviewed DSA and CT.tumor angiogenesis and tumor staining,Karnof-sky Performance Scores(KPS),postoperative adverse events and complications was evaluated.PFS and the survival rate of three months,six months,one year and two years was estimated.Results Tumor angiogenesis and staining were significantly lower in treatment group than those of the control group(P 0.05).KPS scores in the two groups had no significant difference before and after treatment(P >0.05 ).PFS,one year and two years survival rate were better in treatment group than in the control group(P <0.05).Conclusion Combined appli-cation of continuous low-dose oral Tegafur,Gimeracil and Oteracil Potassium Capsules and small dose TACE was significantly su-perior to TACE alone in the treatment of primary hepatocarcinoma patients.
ABSTRACT
Objective: To evaluate the efficacy and toxicity of docetaxel combined with tegafur,gimeracil and oteracil potassium (S-1) capsules in the treatment of patients with advancedadenocarcinoma of esophagogastric junction (AEG). Methods: Fifty-eight patients with advanced AEGwere recruited in this study between January 2009 and January 2011. All patients were treated withchemotherapy of docetaxel (35 mg·m-2·d-1 on d 1 and d 8; intravenous injection) combined with S-1capsule (70 mg/m2 daily for 14 days). The chemotherapy cycle was repeated every 21 days. The short-termresponse and the toxicity were evaluated every two cycles and one cycle, respectively. The follow-upexaminations were performed in all patients, and the survival was calculated. Results: Of the 58 patients,there were 5 patients (8.6%) with complete response, 21 patients (36.2%) with partial response, 18patients (31.0%) with stable disease, and 14 patients (24.1%) with progressive disease. The total responserate was 44.8% (26/58). The median time to progression was 8.0 months, and the median survival timewas 10.5 months. The major toxicities included leucopenia, stomatitis, hand-foot syndrome and adversereactions of gastrointestinal tract. The rate of grade ¢ó-¢ô leucopenia was 25.9% (15/58). Conclusion: Docetaxel combined with S-1 capsule is effective and tolerable in the treatment of patients with advanced AEG. Copyright© 2011 by TUMOR.